• Home
  • » 
  • Reports
  • » 
  • Peptide Therapeutics: Contract API Manuf...

Peptide Therapeutics Manufacturing Market

Peptide Therapeutics: Contract API Manufacturing Market by Scale of Operation, Type of Synthesis Method Used, Company Size and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2022

  • Pages
    294

  • View Count
    16538

  • Buy Now

Example Insights

This image highlights the context of Peptide Therapeutics Market report. Given the prohibitive entry costs and complex production protocols associated with peptide manufacturing, stakeholders are increasingly relying on CMOs for clinical and commercial scale production of novel peptides This image provides list of Peptide Therapeutics Contract API Manufacturers. More than 70 companies currently claim to manufacture peptide-based therapeutics; the market landscape is fragmented, featuring the presence of both established players and new entrants This image presents current market landscape of Peptide Therapeutics Contract API Manufacturers. Industry players employ multiple synthesis and purification techniques while manufacturing peptide APIs across different scales of operation This image presents the market trend of Peptide Therapeutics Contract API Manufacturers. Majority of the firms in this domain were established before 2001; in terms of geographical presence, Asia Pacific and Europe, with maximum number of facilities, are the hubs for contract peptide manufacturing This image highlights the geographical distribution of Peptide Therapeutics Contract API Manufacturers. 110+ dedicated facilities have been established by peptide contract manufacturers; a significant number of firms are offering services for cyclic peptides
This image highlights competitive analysis of players engaged in the domain of Peptide Therapeutics Contract API Manufacturing. In pursuit of building a competitive edge, peptide contract manufacturers are actively upgrading / expanding their existing capabilities in order to enhance their respective portfolios of offerings This image highlights the partnership activity undertaken by players engaged in Peptide Therapeutics Market. The growing interest of stakeholders is evident from the rise in partnership activity; in recent years, a considerable share of deals were inked for manufacturing and product / process development purposes This image provides details on the recent expansions undertaken by players engaged in Peptide Therapeutics Market. In order to meet the rising demand for peptide APIs and finished products, CMOs have made elaborate investments to expand their existing capacities and capabilities; this trend is most pronounced in the US and the UK This image provides information about completed, ongoing and planned clinical studies of Peptide Therapeutics. In the last decade, over 1,300 trials, enrolling close to 0.43 million patients suffering from a myriad of disease indications, have been registered across the globe to evaluate the efficacy of peptide-based drugs This image highlights the estimates of annual commercial and clinical demand for peptide therapeutics. Owing to the fact that peptide-based drugs are being used progressively for the treatment of various diseases, the demand is indubitably rising and expected to grow at annualized rate of over 10% in the near future
This image provides information on the overall, installed capacity for manufacturing peptides. 65% of the global peptide manufacturing capacity is installed in facilities of well-established service providers; stakeholders are anticipated to invest in building incremental capacity in the coming decade This image provides list of Peptide-based Therapy Developers as Potential Strategic Partners. We have identified several peptide-based drug developers which are anticipated to forge strategic manufacturing alliances with contract service providers to further augment their service offerings This image describes the total cost of ownership for a peptide contract manufacturing service provider. Our proprietary total cost of ownership model presents an informed estimate of direct and indirect expenses while setting up a contract manufacturing facility in different regions This image highlights the market segments of Peptide Therapeutics Market. The projected opportunity for peptide therapeutics contract service providers is likely to be well distributed across different segments and is estimated to grow at an annualized rate of 13.6%  

Report Description

Peptide Therapeutics Manufacturing Market Overview

The peptide therapeutics contract API manufacturing market is estimated to be worth $1.7 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 13.6% during the forecast period. Over the years, the popularity of biologics has led to an evident shift in the focus of pharmaceutical companies, from traditional interventions towards more complex and advanced pharmacological interventions, such as peptide therapeutics. Since the discovery of insulin, the peptide therapeutics market has evolved significantly. Presently, over 80 peptide-based drugs are available in the market for the treatment of an array of diseases, including cancer, chronic pain, diabetes, HIV infection, multiple sclerosis and osteoporosis. Further, since 2017, more than 10 peptide-based drugs have been approved by the USFDA. Of these, LupkynisTM and Zegalogue® were recently approved in 2021, while ImcivreeTM, Victoza®, LUPRON DEPOT®, Zoladex®, Sandostatin® and Somatuline® received approval in 2020. In this context, 1,000+ clinical trials have been / are being conducted to evaluate the therapeutic viability and future potential of novel peptides across various phases of development. The increasing popularity of this class of drugs can be attributed to their high specificity, affinity, less drug-drug interactions, diverse biological and chemical activity (enabling the enhancement of their half-lives), proven pharmacological value and favorable safety profiles. Considering the various advantages offered by such drugs, the demand for peptide-based therapeutics is increasing at a considerable pace. 

It is worth highlighting that the peptide synthesis and purification domain is fraught with several challenges, including complexities associated with synthesis of complex, long chain macromolecules, which is known to affect the product yield and purity. In order to mitigate the aforementioned challenges, several players engaged in this domain prefer to outsource their operations to peptide contract manufacturers. Currently, more than 60 contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) claim to offer services for the development, design, manufacturing and purification of peptides. Owing to the fact that a large number of peptide therapeutic developers are outsourcing various aspects of their business processes, several CMOs / CDMOs have become one-stop-shops to cater to the diverse needs of peptide therapeutics developers. Considering the ongoing innovation in production technologies, purification techniques, evolving pipeline and increasing demand for peptide-based drug candidates, we believe that developer companies are likely to continue relying on contract manufacturing service providers and the market is inclined to witness a steady growth in the coming decade. 

As pharma companies resume full-scale operation after the COVID-19 outbreak, the demand for large-scale peptide therapeutics contract API manufacturing is expected to increase significantly. It is worth highlighting that a number of peptide-based COVID-19 vaccines are being developed by pharmaceutical companies which further accelerate the high demand for peptide manufacturing service providers in order to scale-up production of these novel therapeutics post their approval, in order to meet the global demand.

Scope of the Report

The “Peptide Therapeutics: Contract API Manufacturing Market by Scale of Operation (Preclinical / Clinical and Commercial), Type of Synthesis Method Used (Chemical Synthesis Method and Non-Chemical Synthesis Method), Company Size (Small, Mid-sized and Large), and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of therapeutic peptides, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed overview of the current market landscape of companies offering peptide contract manufacturing services, along with information on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location of CMO, number and location of their respective facilities, type of peptide synthesis method used (chemical and non-chemical), types of peptide modification services offered, type of peptide purification technology used (HPLC / UPLC, Ion-Exchange Chromatography and Size-Exchange Chromatography) and regulatory accreditations / certifications received.   
  • An insightful company competitiveness analysis of prominent peptide contract manufacturers, based on several relevant parameters, such as service strength (in terms of experience of the service provider), and capabilities related to contract manufacturing of peptides (such as type of product, type of service(s) offered, number of manufacturing facilities, scale of operation, type of synthesis method used, type of purification technique used, and type of peptide modification).
  • Elaborate profiles of key players (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key executives, details related to peptide contract manufacturing services offered, recent developments, and an informed future outlook.
  • An analysis on the recent developments within the peptide contract manufacturing industry, highlighting information on several partnerships and collaborations and facility expansions that have taken place in this domain, during the period 2016-2021. 
  • An in-depth analysis of completed, ongoing, and planned clinical studies focused on peptide therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus and key geographical regions.
  • A detailed analysis of peptide contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as number of CMOs, number of clinical sites, number of clinical trials, number of patients enrolled, number of peptide manufacturing facilities, type of product, number of clinical / commercial manufacturing CMOs, demand for peptide therapeutics and installed capacity.
  • Informed estimates of the annual commercial and clinical demand for peptide therapeutics, based on several relevant parameters, such as target patient population, dosing frequency and dose strength.
  • An estimate of the overall, installed capacity for manufacturing peptides, based on data reported by industry stakeholders in the public domain; the analysis takes into consideration the distribution of available peptide production capacity across companies of different sizes (small, mid-sized, large and very large firms), scale of operation (clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific). 
  • An analysis highlighting potential strategic partners segregated based on the likelihood of entering into collaboration with peptide therapeutics developers. These players have been shortlisted based on several relevant parameters, such as pipeline strength, pipeline maturity, year of establishment and company size.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by peptide drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A region-wise, detailed analysis of the total cost of ownership for a peptide contract manufacturing service provider. It features an informed estimate of direct and indirect expenses taking into consideration 11 relevant parameters, over a span of 10 years.
  • A discussion on regulatory guidelines related to peptide manufacturing, highlighting the key differences across various geographies, including the US, Europe, Australia, China, India, Japan and South Korea. It also includes details related to the various challenges, related to regulatory scrutiny, faced by peptide manufacturers.
  • An insightful discussion on how the recent COVID-19 pandemic is likely to impact the peptide contract manufacturing market, along with information on the key initiatives undertaken by service providers to overcome the challenges faced due to the pandemic.
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics. 

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the peptide contract manufacturing market, based on several relevant parameters, such as projected growth of overall peptide-based products market, cost of goods sold and direct manufacturing costs. We have developed an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, over the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] scale of operation (preclinical / clinical and commercial) [B] type of synthesis method used [C] company size (small, mid-sized and large), and [D] key geographical regions (North America, Europe, Asia Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s evolution. 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in offering contract manufacturing services for peptide therapeutics?
  • What are the different partnerships and expansion initiatives undertaken by peptide therapeutics contract manufacturers in the recent past?
  • Which regions represent the current key contract manufacturing hubs for peptide therapeutics?
  • What is the current, installed capacity for contract manufacturing of peptides therapeutics?
  • What is the current, global demand for peptide therapeutics? How is the demand for such candidates likely to evolve in the foreseen future?    
  • What percentage of the peptide therapeutics manufacturing operations are presently outsourced?
  • What factors should be taken into consideration while deciding whether the manufacturing operations for peptide therapeutics should be kept in-house or outsourced?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the peptide contract manufacturing market and its likely evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to peptides, including a brief overview of different peptide classes, popular methods used for peptide synthesis and modification. It also highlights the different peptide purification strategies that are available in the market. Further, it includes information on the various applications of peptides, along with a brief overview of contract manufacturing. It also provides a detailed discussion on the need for outsourcing peptide manufacturing operations and its key advantages. 

Chapter 4 features a detailed discussion on the regulatory landscape related to peptide contract manufacturers across various geographies, such as the US, Europe, Australia, China, India, Japan and South Korea. It also includes details related to the various challenges, related to regulatory scrutiny, faced by peptide manufacturers.

Chapter 5 provides an overview of the current market landscape of companies offering peptide contract manufacturing services, along with information on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location of CMO, number and location of their respective facilities, type of peptide synthesis method used (chemical and non-chemical), types of peptide modification services offered, type of peptide purification technology used (HPLC / UPLC, Ion-Exchange Chromatography and Size-Exchange Chromatography), and regulatory accreditations / certifications received.

Chapter 6 features an insightful company competitiveness analysis of prominent peptide contract manufacturers, based on several relevant parameters, such as service strength (in terms of experience of the service provider), and capabilities related to contract manufacturing of peptides (such as type of product, type of service(s) offered, number of manufacturing facilities, scale of operation, type of synthesis method used, type of purification technique used, and type of peptide modification).

Chapter 7 features profiles of key players (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key executives, details related to peptide contract manufacturing services offered, recent developments, and an informed future outlook.

Chapter 8 presents an analysis of the recent developments within the peptide contract manufacturing industry, highlighting information on several partnerships and collaborations and facility expansions that have taken place in this domain, during the period 2016-2021.

Chapter 9 presents an in-depth analysis of completed, ongoing, and planned clinical studies focused on peptide therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus and key geographical regions.

Chapter 10 presents a detailed analysis of peptide contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as number of CMOs, number of clinical sites, number of clinical trials, number of patients enrolled, number of peptide manufacturing facilities, type of product, number of clinical / commercial manufacturing CMOs, demand for peptide therapeutics and installed capacity.

Chapter 11 features a detailed analysis of the annual commercial and clinical demand for peptide therapeutics, based on several relevant parameters, such as target patient population, dosing frequency and dose strength.

Chapter 12 features an analysis of the overall, installed capacity for manufacturing peptides, based on data reported by industry stakeholders in the public domain; the analysis takes into consideration the distribution of available peptide production capacity across companies of different sizes (small, mid-sized and large firms), scale of operation (clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific).

Chapter 13 presents potential strategic partners segregated based on the likelihood of entering into collaboration with peptide therapeutics developers. These players have been shortlisted based on several relevant parameters, such as pipeline strength, pipeline maturity, year of establishment and company size.

Chapter 14 presents qualitative analysis highlighting the various factors that need to be taken into consideration by peptide drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 15 features a detailed analysis of the total cost of ownership for a peptide contract manufacturing service provider. It features an informed estimate of direct and indirect expenses taking into consideration 11 relevant parameters, over a span of 10 years.

Chapter 16 presents a detailed market forecast analysis, highlighting the likely growth of the peptide contract manufacturing market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] scale of operation (preclinical / clinical and commercial) [B] type of synthesis method used [C] company size (small, mid-sized and large), and [D] key geographical regions (North America, Europe, Asia Pacific and Rest of the World).

Chapter 17 presents an insightful discussion on how the recent COVID-19 pandemic is likely to impact the peptide contract manufacturing market, along with information on the key initiatives undertaken by service providers to overcome the challenges faced due to the pandemic.

Chapter 18 provides a detailed discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

Chapter 19 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the peptide CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of peptide CMOs.

Chapter 20 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the peptide therapeutics contract manufacturing market.

Chapter 21 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Peptides
3.2.1. Structural Analysis of Peptides
3.2.2. Classification of Peptides
3.2.3. Peptide Synthesis

3.2.4. Type of Peptide Modification
3.2.4.1. N-terminal Modification
3.2.4.2. Internal Modification
3.2.4.3. C-terminal Modification
3.2.4.4. Other Modifications

3.2.5. Peptide Purification
3.2.5.1. Key Guidelines for Peptide Purity

3.3. Overview of Contract Manufacturing
3.3.1. Need for Outsourcing Peptide Manufacturing Operations
3.3.2. Key Considerations for Selecting a CMO Partner
3.3.3. Advantages of Outsourcing Manufacturing Services
3.3.4. Risks and Challenges Associated with Outsourcing Peptide Manufacturing Operations
3.4. Future Perspectives

4. REGULATORY LANDSCAPE
4.1. Chapter Overview
4.2. Regulatory Scenario: North America
4.2.1. The US Scenario
4.2.1.1. Overview
4.2.1.2. General Guidelines

4.3. Regulatory Scenario: Europe
4.3.1. The European Scenario
4.3.1.1. Overview
4.3.1.2. General Guidelines

4.4. Regulatory Scenario: Asia Pacific
4.4.1. Overview
4.4.2. Australian Scenario
4.4.2.1. General Guidelines
4.4.3. Chinese Scenario
4.4.3.1. General Guidelines
4.4.4. Indian Scenario
4.4.4.1. General Guidelines
4.4.5. Japanese Scenario
4.4.5.1. General Guidelines
4.4.6. South Korean Scenario
4.4.6.1. General Guidelines

4.5. Key Challenges Associated with Peptide Manufacturing

5. COMPETITIVE LANDSCAPE
5.1 Chapter Overview
5.2 Contract Peptide API Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Location of Manufacturing Facility (Continent-wise)
5.2.5. Analysis by Location of Manufacturing Facility (Country-wise)
5.2.6. Analysis by Type of Product
5.2.7. Analysis by Type of Service(s) Offered
5.2.8. Analysis by Scale of Operation
5.2.9. Analysis by Type of Peptide Synthesis Method Used
5.2.10. Analysis by Type of Peptide Modification Services Offered
5.2.11. Analysis by Type of Purification Technology Used
5.2.12. Analysis by Regulatory Accreditations / Certifications Received

5.3. List of Custom Peptide Manufacturers

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers
6.4.1 Company Competitiveness: Small Companies
6.4.2 Company Competitiveness: Mid-sized Companies
6.4.3. Company Competitiveness: Large Companies

7. COMPANY PROFILES
7.1 Chapter Overview
7.2. Contract Peptide API Manufacturers Based in North America
7.2.1. AmbioPharm
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.3. Manufacturing Facilities and Capabilities
7.2.1.4. Recent Development and Future Outlook

7.2.2. CPC Scientific
7.2.2.1. Company Overview
7.2.2.2. Service Portfolio
7.2.2.3. Manufacturing Facilities and Capabilities
7.2.2.4. Recent Developments and Future Outlook

7.2.3. Creative Peptides
7.2.3.1. Company Overview
7.2.3.2. Service Portfolio
7.2.3.3. Manufacturing Facilities and Capabilities
7.2.3.4. Recent Developments and Future Outlook

7.2.4. CSBio
7.2.4.1. Company Overview
7.2.4.2. Service Portfolio
7.2.4.3. Manufacturing Facilities and Capabilities
7.2.4.4. Recent Developments and Future Outlook

7.3. Contract Peptide API Manufacturers Based in Europe
7.3.1. Bachem
7.3.1.1. Recent Developments and Company Overview
7.3.1.2. Service Portfolio
7.3.1.3. Manufacturing Facilities and Capabilities
7.3.1.4. Recent Developments and Future Outlook

7.3.2. BCN Peptide
7.3.2.1. Company Overview
7.3.2.2. Service Portfolio
7.3.2.3. Manufacturing Facilities and Capabilities
7.3.2.4. Recent Developments and Future Outlook

7.3.3. Corden Pharma
7.3.3.1. Company Overview
7.3.3.2. Service Portfolio
7.3.3.3. Manufacturing Facilities and Capabilities
7.3.3.4. Recent Developments and Future Outlook

7.3.4. PolyPeptide
7.3.4.1. Company Overview
7.3.4.2. Service Portfolio
7.3.4.3. Manufacturing Facilities and Capabilities
7.3.4.4. Recent Developments and Future Outlook

7.3.5. Senn Chemicals
7.3.5.1. Company Overview
7.3.5.2. Service Portfolio
7.3.5.3. Manufacturing Facilities and Capabilities
7.3.5.4. Recent Developments and Future Outlook

7.4. Contract Peptide API Manufacturers Based in Asia Pacific
7.4.1. Auspep
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.3. Manufacturing Facilities and Capabilities
7.4.1.4. Recent Developments and Future Outlook

7.4.2. Chinese Peptide
7.4.2.1. Company Overview
7.4.2.2. Service Portfolio
7.4.2.3. Manufacturing Facilities and Capabilities
7.4.2.4. Recent Developments and Future Outlook

7.4.3. Hybio Pharmaceutical
7.4.3.1. Company Overview
7.4.3.2. Service Portfolio
7.4.3.3. Manufacturing Facilities and Capabilities
7.4.3.4. Recent Developments and Future Outlook

7.4.4. Peptide Institute
7.4.4.1. Company Overview
7.4.4.2. Service Portfolio
7.4.4.3. Manufacturing Facilities and Capabilities
7.4.4.4. Recent Developments and Future Outlook

7.4.5. ScinoPharm
7.4.5.1. Company Overview
7.4.5.2. Service Portfolio
7.4.5.3. Manufacturing Facilities and Capabilities
7.4.5.4. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS
8.1. Chapter Overview
8.2. Partnerships Models
8.3. Peptide Therapeutics Contract API Manufacturers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Scale of Operation
8.3.4. Analysis by Region (Continent-wise)
8.3.4.1. Analysis by Region (Country-wise)
8.3.4.2. Intercontinental and Intracontinental Distribution

8.4. Expansion Models
8.5. List of Recent Expansions
8.5.1. Analysis by Year of Expansion
8.5.2. Analysis by Type of Expansion
8.5.3. Analysis by Location of Expansion (Continent-wise)
8.5.4. Analysis by Location of Expansion (Country-wise)

8.6. Emerging Peptide Synthesis Technologies
8.6.1. Chemo-Enzymatic Peptide Synthesis Technology
8.6.2. Continuous Flow Technology
8.6.3. Green Chemistry

9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Peptide Therapeutics: List of Clinical Trials
9.3.1. Analysis by Trial Status
9.3.2. Analysis by Trial Registration Year
9.3.3. Analysis by Type of Masking
9.3.4. Analysis by Type of Intervention Model
9.3.5. Analysis by Study Design
9.3.6. Analysis by Phase of Development
9.3.7. Analysis by Type of Sponsor
9.3.8. Most Active Players: Analysis by Number of Trials Registered
9.3.9. Analysis by Trial Registration Year and Trial Status
9.3.10. Analysis by Trial Registration Year and Geography
9.3.11. Analysis by Number of Trials, Trial Status and Geography
9.3.12. Analysis by Number of Trials, Trial Registration Year and Geography

9.4. Analysis of Enrolled Patient Population
9.4.1. Analysis of Enrolled Patient Population by Geography
9.4.2. Analysis by Number of Patients Enrolled, Trial Status and Geography
9.4.3. Analysis by Phase of Development, Trial Registration Year and Number of Patients Enrolled
9.4.4. Analysis of Number of Clinical Trials by Geography

10. REGIONAL CAPABILITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Overall Landscape of Contract Peptide API Manufacturers
10.4. Contract Peptide API Manufacturers in North America
10.5. Contract Peptide API Manufacturers in Europe
10.6. Contract Peptide API Manufacturing in Asia Pacific

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Peptide API Manufacturing: Overall Annual Demand
11.3.1. Analysis by Geography

12. CAPACITY ANALYSIS
12.1. Chapter Overview
12.2. Assumptions and Methodology
12.3. Peptide API Manufacturing: Installed Global Capacity
12.3.1. Analysis by Company Size
12.3.2. Analysis by Scale of Operation
12.3.3. Analysis by Location of Manufacturing Facility
12.3.4. Analysis by Company Size and Location of Manufacturing Facility
12.3.5. Analysis by Scape of Operation and Location of Manufacturing Facility

12.4. Concluding Remarks

13. LIKELY PARTNERS FOR PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING SERVICE PROVIDERS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Potential Strategic Partners for Peptide Contract Manufacturers

14. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
14.1. Chapter Overview
14.2. Assumptions and Parameter Definitions
14.2.1. Scenario 1
14.2.2. Scenario 2
14.2.3. Scenario 3
14.2.4. Scenario 4
14.3. Concluding Remarks

15. TOTAL COST OF OWNERSHIP IN PEPTIDE CONTRACT MANUFACTURING ORGANIZATION
15.1. Chapter Overview
15.2. Expenditures Incurred by a Peptide Contract Manufacturing Organization
15.2.1. Capital Expenditures (CAPEX)
15.2.2. Operational Expenditures (OPEX)
15.3. Assumptions and Methodology
15.4. Total Cost of Ownership of Peptide Contract Manufacturing Organization, 2021-2030
15.5. Total Cost of Ownership of Peptide Contract Manufacturing Organization: Distribution by CAPEX and OPEX, 2021-2030
15.5.1. Total Cost of Ownership of Peptide Contract Manufacturing Organization: Distribution by CAPEX, 2021-2030
15.5.2. Total Cost of Ownership of Peptide Contract Manufacturing Organization: Distribution by OPEX, 2021-2030
15.6. Concluding Remarks

16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Assumptions and Forecast Methodology
16.3. Overall Peptide Therapeutics Contract Manufacturing Market, 2022-2035
16.3.1. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035
16.3.2. Peptide Therapeutics Contract FDF Manufacturing Market, 2022-2035

16.4. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Scale of Operation
16.5. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Type of Peptide Synthesis Method Used
16.5.1. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Type of Chemical Synthesis Method Used

16.6. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Company Size
16.7. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Key Geographical Regions
16.7.1. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035
16.7.1.1. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Small Companies
16.7.1.2. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Mid-sized Companies
16.7.1.3. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Large Companies
16.7.1.4. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Preclinical / Clinical Scale Operations
16.7.1.5. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Commercial Scale Operations
16.7.1.6. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Chemical Synthesis Methods
16.7.1.8. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Non-Chemical Synthesis Methods

16.7.2. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035
16.7.2.1. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Small Companies
16.7.2.2. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Mid-sized Companies
16.7.2.3. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Large Companies
16.7.2.4. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Preclinical / Clinical Scale Operations
16.7.2.5. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Commercial Scale Operations
16.7.2.6. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Chemical Synthesis Methods
16.7.2.8. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Non-Chemical Synthesis Methods

16.7.3. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035
16.7.3.1. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Small Companies
16.7.3.2. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Mid-sized Companies
16.7.3.3. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Large Companies
16.7.3.4. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Preclinical / Clinical Scale Operations
16.7.3.5. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Commercial Scale Operations
16.7.3.6. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Chemical Synthesis Methods
16.7.3.7. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Non-Chemical Synthesis Methods

17. IMPACT OF THE COVID-19 PANDEMIC ON THE PEPTIDE API CONTRACT MANUFACTURING MARKET
17.1. Chapter Overview
17.2. Current Options and Recuperative Initiatives of Key Players
17.2.1. Bachem
17.2.2. CPC Scientific
17.2.3. Corden Pharma
17.2.4. PolyPeptide
17.2.5. Wuxi AppTec

17.3. Impact on Peptide API Contract Manufacturing Market

18. SWOT ANALYSIS
18.1. Chapter Overview
18.2. Strengths
18.3. Weaknesses
18.4. Opportunities
18.5. Threats
18.6. Comparison of SWOT Factors
18.7. Concluding Remark

19. CONCLUSION
19.1. Chapter Overview

20. SURVEY TRANSCRIPT(S)

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

List Of Figures

Figure 3.1. Peptide Synthesis Strategies
Figure 3.2. Peptide Modification Techniques
Figure 3.3. Types of Third-Party Service Providers
Figure 4.1. Regulatory Landscape: Peptide Classification in the US
Figure 5.1. Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Establishment
Figure 5.2. Peptide Therapeutics Contract API Manufacturers: Distribution by Company Size
Figure 5.3. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Headquarters
Figure 5.4. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Manufacturing Facilities (Continent-wise)
Figure 5.5. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 5.6. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Product
Figure 5.7. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Service(s) Offered
Figure 5.8. Peptide Therapeutics Contract API Manufacturers: Distribution by Scale of Operation
Figure 5.9. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Synthesis Method Used
Figure 5.10. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Modification Services Offered
Figure 5.11. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Purification Technology Used
Figure 5.12. Peptide Therapeutics Contract API Manufacturers: Distribution by Regulatory Accreditations / Certifications Received
Figure 6.1. Company Competitiveness Analysis: Dot-Plot Representation (Small Players)
Figure 6.2. Company Competitiveness Analysis: Dot-Plot Representation (Mid-sized Players)
Figure 6.3. Company Competitiveness Analysis: Dot-Plot Representation (Large Players)
Figure 7.1. AmbioPharm: Service Portfolio
Figure 7.2. CPC Scientific: Service Portfolio
Figure 7.3. Creative Peptides: Service Portfolio
Figure 7.4. CSBio: Service Portfolio
Figure 7.5. Bachem: Service Portfolio
Figure 7.6. BCN Peptide: Service Portfolio
Figure 7.7. Corden Pharma: Service Portfolio
Figure 7.8. PolyPeptide: Service Portfolio
Figure 7.9. Senn Chemical: Service Portfolio
Figure 7.10. Auspep: Service Portfolio
Figure 7.11. Chinese Peptide: Service Portfolio
Figure 7.12. Hybio Pharmaceuticals: Service Portfolio
Figure 7.13. Peptide Institute: Service Portfolio
Figure 7.14. ScinoPharm: Service Portfolio
Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Distribution by Scale of Operation
Figure 8.4. Partnerships and Collaborations: Distribution by Region (Continent-wise)
Figure 8.5. Partnerships and Collaborations: Distribution by Region (Country-wise)
Figure 8.6. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 8.7. Recent Expansions: Distribution by Year of Expansion
Figure 8.8. Recent Expansions: Distribution by Type of Expansion
Figure 8.9. Recent Expansions: Distribution by Location of Expansion (Continent-Wise)
Figure 8.10. Recent Expansions: Distribution by Location of Expansion (Country-Wise)
Figure 8.11. Chemo-Enzymatic Peptide Synthesis Technology: Advantages and Disadvantages
Figure 8.12. Continuous Flow Technology: Advantages and Disadvantages
Figure 8.13. Green Chemistry: Advantages and Disadvantages
Figure 9.1. Clinical Trial Analysis: Distribution by Trial Status
Figure 9.2. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 9.3. Clinical Trial Analysis: Distribution by Type of Masking
Figure 9.4. Clinical Trial Analysis: Distribution by Intervention Model Adopted
Figure 9.5. Clinical Trial Analysis: Distribution by Study Design
Figure 9.6. Clinical Trial Analysis: Distribution by Phase of Development
Figure 9.7. Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 9.8. Most Active Players: Distribution by Number of Clinical Trials
Figure 9.9. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 9.10. Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 9.11. Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Figure 9.12. Clinical Trial Analysis: Distribution by Number of Trials, Trial Registration Year and Geography
Figure 9.13. Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 9.14. Clinical Trial Analysis: Distribution of Enrolled Patients Population by Geography
Figure 9.15. Clinical Trial Analysis: Distribution by Number of Patients Enrolled, Trial Status and Geography
Figure 9.16. Clinical Trial Analysis: Distribution by Phase of Development, Trial Registration Year and Number of Patients Enrolled
Figure 9.17. Clinical Trial Analysis: Distribution of Number of Clinical Trials by Geography
Figure 10.1. Regional Capability Analysis: Distribution by Location of Manufacturing Facilities
Figure 10.2. Regional Capability Analysis: North America
Figure 10.3. Regional Capability Analysis: Europe
Figure 10.4. Regional Capability Analysis: Asia Pacific
Figure 11.1. Demand Analysis: Annual Demand for Peptide Therapeutics (in Kilograms)
Figure 11.2. Demand Analysis: Distribution by Geographical Location
Figure 12.1. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Company Size
Figure 12.2. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
Figure 12.3. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 12.4. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility
Figure 12.5. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Company Size and Location of Manufacturing Facility
Figure 12.6. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 14.1. Make versus Buy Decision Making Framework
Figure 14.2. Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 15.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 15.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 15.3 Total Cost of Ownership: Other Costs
Figure 15.4 Total Cost of ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2021-2030 (USD Million)
Figure 15.5 Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, 2021-2030 (USD Million)
Figure 15.6 Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2021-2030: Distribution by CAPEX (USD Million)
Figure 15.7 Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2021-2030: Distribution by OPEX (USD Million)
Figure 16.1. Overall Peptide Therapeutics Contract Manufacturing Market, 2022-2035 (USD Billion)
Figure 16.2. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035 (USD Billion)
Figure 16.3. Peptide Therapeutics Contract FDF Manufacturing Market, 2022-2035 (USD Billion)
Figure 16.4. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 16.5. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method Used, 2022-2035 (USD Billion)
Figure 16.6. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Chemical Synthesis Methods Used, 2022-2035 (USD Billion)
Figure 16.7. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Methods Used, 2028 and 2035
Figure 16.8. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2022-2035 (USD Million)
Figure 16.9. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Billion)
Figure 16.10. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035 (USD Billion)
Figure 16.11. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Small Companies (USD Billion)
Figure 16.12. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Mid-sized Companies (USD Billion)
Figure 16.13. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Large Companies (USD Billion)
Figure 16.14. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Preclinical / Clinical Operations (USD Billion)
Figure 16.15. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Commercial Operations (USD Billion)
Figure 16.16. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Chemical Synthesis Method (USD Million)
Figure 16.17. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
Figure 16.18. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035 (USD Million)
Figure 16.19. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Small Companies (USD Million)
Figure 16.20. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Mid-sized Companies (USD Million)
Figure 16.21. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Large Companies (USD Million)
Figure 16.22. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Preclinical / Clinical Operations (USD Million)
Figure 16.23. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Commercial Operations (USD Million)
Figure 16.24. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Chemical Synthesis Method (USD Million)
Figure 16.25. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
Figure 16.26. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035 (USD Million)
Figure 16.27. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Small Companies (USD Million)
Figure 16.28. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Mid-sized Companies (USD Million)
Figure 16.29. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Large Companies (USD Million)
Figure 16.30. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Preclinical / Clinical Operations (USD Million)
Figure 16.31. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Commercial Operations (USD Million)
Figure 16.32. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Chemical Synthesis Method (USD Million)
Figure 16.33. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
Figure 17.1. Peptide Therapeutics Contract API Manufacturing Services Market, 2016-2031: COVID-19 Impact Scenario (USD Billion)
Figure 18.1. Contract Peptide API Manufacturing: SWOT Analysis
Figure 18.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 3.1. Comparison of Major Peptide Synthesizing Processes
Table 3.2. Chromatographic Techniques
Table 5.1. List of Contract Peptide API Manufacturers
Table 5.2. Peptide Therapeutics Contract API Manufacturers: Information on Type of Product
Table 5.3. Peptide Therapeutics Contract API Manufacturers: Information on Type of Service(s) Offered
Table 5.4. Peptide Therapeutics Contract API Manufacturers: Information on Scale of Operation
Table 5.5. Peptide Therapeutics Contract API Manufacturers: Information on Type of Peptide Synthesis Method Used
Table 5.6. Peptide Therapeutics Contract API Manufacturers: Information on Type of Peptide Modification Service Offered
Table 5.7. Peptide Therapeutics Contract API Manufacturers: Information on Type of Purification Technology Used
Table 5.8. Peptide Therapeutics Contract API Manufacturers: Information on Regulatory Accreditations / Certifications Received
Table 5.9. List of Custom Peptide Manufacturers
Table 6.1 Company Competitiveness Analysis: Small Companies
Table 6.2 Company Competitiveness Analysis: Mid-sized Companies
Table 6.3 Company Competitiveness Analysis: Large Companies
Table 7.1. AmbioPharm: Company Overview
Table 7.2. AmbioPharm: Overview of Manufacturing Capabilities
Table 7.3. AmbioPharm: Recent Developments and Future Outlook
Table 7.4. CPC Scientific: Company Overview
Table 7.5. CPC Scientific: Overview of Manufacturing Capabilities
Table 7.6. Creative Peptides: Company Overview
Table 7.7. Creative Peptides: Overview of Manufacturing Capabilities
Table 7.8. CSBio: Company Overview
Table 7.9. CSBio: Overview of Manufacturing Capabilities
Table 7.10. Bachem: Company Overview
Table 7.11. Bachem: Overview of Manufacturing Capabilities
Table 7.12. BCN Peptide: Company Overview
Table 7.13. BCN Peptide: Overview of Manufacturing Capabilities
Table 7.14. Corden Pharma: Company Overview
Table 7.15. Corden Pharma: Overview of Manufacturing Capabilities
Table 7.16. Corden Pharma: Recent Developments and Future Outlook
Table 7.17. PolyPeptide: Company Overview
Table 7.18. PolyPeptide: Overview of Manufacturing Capabilities
Table 7.19. Senn Chemicals: Company Overview
Table 7.20. Senn Chemicals: Overview of Manufacturing Capabilities
Table 7.21. Auspep: Company Overview
Table 7.22. Auspep: Overview of Manufacturing Capabilities
Table 7.23. Chinese Peptide: Company Overview
Table 7.24. Chinese Peptide: Overview of Manufacturing Capabilities
Table 7.25. Hybio Pharmaceuticals: Company Overview
Table 7.26. Hybio Pharmaceuticals: Overview of Manufacturing Capabilities
Table 7.27. Peptide Institute: Company Overview
Table 7.28. Peptide Institute: Overview of Manufacturing Capabilities
Table 7.29. ScinoPharm: Company Overview
Table 7.30. ScinoPharm: Overview of Manufacturing Capabilities
Table 8.1. Contract Peptide API Manufacturers: List of Recent Partnerships, 2016-2021
Table 8.2. Contract Peptide API Manufacturers: List of Recent Expansions, 2016-2021
Table 9.1. Peptide Therapeutics: List of Clinical Trials
Table 12.1. Capacity Analysis: Average Capacity for Peptide Synthesis (Dataset)
Table 12.2. Capacity Analysis: List of Companies with Installed Capacity
Table 12.3. Capacity Analysis: Installed Global Capacity
Table 13.1. Industry Players in North America: Most Likely Partners
Table 13.2. Industry Players in North America: Likely Partners
Table 13.3. Industry Players in North America: Less Likely Partners
Table 13.4. Non-Industry Players in North America: Most Likely Partners
Table 13.5. Non-Industry Players in North America: Likely Partners
Table 13.6. Non-Industry Players in North America: Less Likely Partners
Table 13.7. Industry Players in Europe: Most Likely Partners
Table 13.8. Industry Players in Europe: Likely Partners
Table 13.9. Industry Players in Europe: Less Likely Partners
Table 13.10. Non-Industry Players in Europe: Most Likely Partners
Table 13.11. Non-Industry Players in Europe: Likely Partners
Table 13.12. Non-Industry Players in Europe: Less Likely Partners
Table 13.13. Industry Players in Asia-Pacific: Most Likely Partners
Table 13.14. Industry Players in Asia-Pacific: Likely Partners
Table 13.15. Industry Players in Asia-Pacific: Less Likely Partners
Table 13.16. Non-Industry Players in Asia-Pacific: Most Likely Partners
Table 13.17. Non-Industry Players in Asia-Pacific: Likely Partners
Table 13.18. Non-Industry Players in Asia-Pacific: Less Likely Partners
Table 19.1. Peptide Therapeutics Contract API Manufacturing Market: Key Takeaways
Table 21.1. Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Establishment
Table 21.2. Peptide Therapeutics Contract API Manufacturers: Distribution by Company Size
Table 21.3. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Headquarters
Table 21.4. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Manufacturing Facilities (Continent-wise)
Table 21.5. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 21.6. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Product
Table 21.7. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Service(s) Offered
Table 21.8. Peptide Therapeutics Contract API Manufacturers: Distribution by Scale of Operation
Table 21.9. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Synthesis Method Used
Table 21.10. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Modification Services Offered
Table 21.11. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Purification Technology Used
Table 21.12. Peptide Therapeutics Contract API Manufacturers: Distribution by Regulatory Accreditations / Certifications Received
Table 21.13. Company Competitiveness Analysis: Dot-Plot Representation (Small Players)
Table 21.14. Company Competitiveness Analysis: Dot-Plot Representation (Mid-sized Players)
Table 21.15. Company Competitiveness Analysis: Dot-Plot Representation (Large Players)
Table 21.16. Partnerships and Collaborations: Distribution by Year of Partnership
Table 21.17. Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.18. Partnerships and Collaborations: Distribution by Scale of Operation
Table 21.19. Partnerships and Collaborations: Distribution by Region (Continent-wise)
Table 21.20. Partnerships and Collaborations: Distribution by Region (Country-wise)
Table 21.21. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 21.22. Recent Expansions: Distribution by Year of Expansion
Table 21.23. Recent Expansions: Distribution by Type of Expansion
Table 21.24. Recent Expansions: Distribution by Location of Expansion (Continent-Wise)
Table 21.25. Recent Expansions: Distribution by Location of Expansion (Country-Wise)
Table 21.26. Clinical Trial Analysis: Distribution by Trial Status
Table 21.27. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 21.28. Clinical Trial Analysis: Distribution by Type of Masking
Table 21.29. Clinical Trial Analysis: Distribution by Intervention Model Adopted
Table 21.30. Clinical Trial Analysis: Distribution by Study Design
Table 21.31. Clinical Trial Analysis: Distribution by Phase of Development
Table 21.32. Clinical Trial Analysis: Distribution by Type of Sponsor
Table 21.33. Most Active Players: Distribution by Number of Clinical Trials
Table 21.34. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 21.35. Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 21.36. Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Table 21.37. Clinical Trial Analysis: Distribution by Number of Trials, Trial Registration Year and Geography
Table 21.38. Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 21.39. Clinical Trial Analysis: Distribution of Enrolled Patients Population by Geography
Table 21.40. Clinical Trial Analysis: Distribution by Number of Patients Enrolled, Trial Status and Geography
Table 21.41. Clinical Trial Analysis: Distribution by Phase of Development, Trial Registration Year and Number of Patients Enrolled
Table 21.42. Clinical Trial Analysis: Distribution of Number of Clinical Trials by Geography
Table 21.43. Regional Capability Analysis: Distribution by Location of Manufacturing Facilities
Table 21.44. Regional Capability Analysis: North America
Table 21.45. Regional Capability Analysis: Europe
Table 21.46. Regional Capability Analysis: Asia Pacific
Table 21.47. Demand Analysis: Annual Demand for Peptide Therapeutics (in Kilograms)
Table 21.48. Demand Analysis: Distribution by Geographical Location
Table 21.49. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Company Size
Table 21.50. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
Table 21.51. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 21.52. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility
Table 21.53. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Company Size and Location of Manufacturing Facility
Table 21.54. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Scale of Operation and Location of Manufacturing Facility
Table 21.55. Total Cost of Ownership: Capital Expenditures (CAPEX)
Table 21.56. Total Cost of Ownership: Operational Expenditures (OPEX)
Table 21.57. Total Cost of Ownership: Other Costs
Table 21.58. Total Cost of ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2021-2030 (USD Million)
Table 21.59. Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, 2022-2030 (USD Million)
Table 21.60. Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2022-2030: Distribution by CAPEX (USD Million)
Table 21.61. Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2022-2030: Distribution by OPEX (USD Million)
Table 21.62. Overall Peptide Therapeutics Contract Manufacturing Market, 2022-2035 (USD Billion)
Table 21.63. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035 (USD Billion)
Table 21.64. Peptide Therapeutics Contract FDF Manufacturing Market, 2022-2035 (USD Billion)
Table 21.65. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 21.66. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method Used, 2022-2035 (USD Billion)
Table 21.67. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Chemical Synthesis Methods Used, 2022-2035 (USD Billion)
Table 21.68. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Methods Used, 2028 and 2035
Table 21.69. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2022-2035 (USD Million)
Table 21.70. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Billion)
Table 21.71. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035 (USD Billion)
Table 21.72. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Small Companies (USD Billion)
Table 21.73. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Mid-sized Companies (USD Billion)
Table 21.74. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Large Companies (USD Billion)
Table 21.75. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Preclinical / Clinical Operations (USD Billion)
Table 21.76. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Commercial Operations (USD Billion)
Table 21.77. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Chemical Synthesis Method (USD Million)
Table 21.78. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
Table 21.79. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035 (USD Million)
Table 21.80. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Small Companies (USD Million)
Table 21.81. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Mid-sized Companies (USD Million)
Table 21.82. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Large Companies (USD Million)
Table 21.83. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Preclinical / Clinical Operations (USD Million)
Table 21.84. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Commercial Operations (USD Million)
Table 21.85. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Chemical Synthesis Method (USD Million)
Table 21.86. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
Table 21.87. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035 (USD Million)
Table 21.88. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Small Companies (USD Million)
Table 21.89. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Mid-sized Companies (USD Million)
Table 21.90. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Large Companies (USD Million)
Table 21.91. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Preclinical / Clinical Operations (USD Million)
Table 21.92. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Commercial Operations (USD Million)
Table 21.92. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Chemical Synthesis Method (USD Million)
Table 21.94. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
Table 21.95. Peptide Therapeutics Contract API Manufacturing Services Market, 2016-2031: COVID-19 Impact Scenario (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 13therapeutics
  2. 9 Meters Biopharma
  3. AAPPTec
  4. Abbiotec
  5. Abcepta
  6. Abclonal
  7. ABI Scientific
  8. Abzena
  9. ACES Pharma
  10. Activotec 
  11. Adalvo
  12. Adar Biotech
  13. Advanced Accelerator Applications
  14. Advanced ChemTech
  15. Advanced Peptides
  16. Aileron Therapeutics
  17. Ajinomoto Bio-Pharma
  18. Akashi Therapeutics
  19. Albiochem
  20. Allysta Pharmaceuticals
  21. Almac
  22. Alpha Diagnostic
  23. AltaBioscience
  24. Altimmune
  25. AmbioPharm
  26. American Peptide Company
  27. Amgen
  28. AminoPrimeCentral
  29. Amolyt Pharma
  30. Ampio Pharmaceuticals
  31. Amunix 
  32. Amyndas Pharmaceuticals
  33. Anaspec
  34. AnGes
  35. Anji Pharmaceuticals
  36. Antagene
  37. APAC Pharmaceutical
  38. Apellis Pharmaceuticals
  39. Apeptico
  40. APIM Therapeutics
  41. Apitope
  42. APL
  43. Aquestive Therapeutics
  44. Arch Biopartners
  45. Ardena
  46. Ascendia
  47. AsclepiX Therapeutics
  48. Aspen Oss
  49. AstraZeneca
  50. Asymchem
  51. Atlantic Peptides
  52. Atox Bio
  53. Aurigene Pharmaceutical Services 
  54. Aurinia Pharmaceuticals
  55. Auspep
  56. Austin Chemical
  57. Averica
  58. Avilex Pharma
  59. Axon Neuroscience
  60. Baccinex 
  61. Bachem
  62. BAM Biotech
  63. Bayer
  64. BCN Peptides
  65. Bicycle Therapeutics
  66. Bioassay
  67. BioConcept
  68. BioLineRx
  69. Biolingus
  70. Biomarck Pharmaceuticals
  71. BioMarin Pharmaceutical
  72. Biomer Technology
  73. Biopeptek Pharmaceuticals
  74. BioServ
  75. Bio-Synthesis
  76. BioVectra
  77. Boehringer Ingelheim
  78. Boston Therapeutics
  79. Burrard Pharmaceuticals
  80. California Peptide 
  81. Cambridge Peptides
  82. Cambridge Research Biochemicals
  83. CanBas
  84. CanPeptide
  85. Capsugel
  86. Cara Therapeutics
  87. CARBOGEN AMCIS
  88. Carmot Therapeutics
  89. CASLO
  90. CBL
  91. Celtek Peptides
  92. CEM
  93. Cend Therapeutics
  94. Centre for Process Systems Engineering (CPSE)
  95. CHEMI
  96. ChemPartner
  97. ChemPep
  98. Chiasma Pharma
  99. ChinaTech Peptide
  100. Chinese Peptide Company
  101. Chondropeptix
  102. Chrysalis BioTherapeutics
  103. Clinuvel Pharmaceuticals
  104. CohBar
  105. Constant Therapeutics
  106. CordenPharma
  107. Corvid Pharmaceuticals
  108. Covalab
  109. CPC Scientific
  110. Creative Peptides
  111. CreoSalus
  112. CSBio
  113. CureDM
  114. Curia
  115. Curonz
  116. Cytovation
  117. Dalton Pharma
  118. Deca Peptide
  119. Designer Bioscience
  120. Diabetology
  121. Diapin Therapeutics 
  122. Dottikon ES
  123. Eli Lilly
  124. Entera Bio
  125. Enteris BioPharma
  126. Enzene Biosciences
  127. Enzo Life Sciences
  128. EOC Pharma 
  129. Esperance Pharmaceuticals
  130. Eurogentec
  131. Europe Pharmaceutical
  132. F4 Pharma 
  133. Ferring Pharmaceuticals
  134. FirstString Research
  135. Follicum
  136. Formac Pharmaceuticals
  137. Frontier Biotechnologies
  138. Genervon Biopharmaceuticals
  139. Genosphere
  140. Genpro Biotech
  141. GenScript
  142. Genus Oncology
  143. Gila Therapeutics
  144. GlaxoSmithKline
  145. GlioCure
  146. GLyPharma
  147. GlyTech
  148. GP Pharm
  149. Grace
  150. Green Chemistry and Enabling Technologies
  151. IBMM Peptide
  152. Grey Matter Research Foundation
  153. GYRUS Pharma
  154. HAMLET Pharma
  155. Hemmo Pharmaceuticals
  156. HighTide Therapeutics
  157. Hybio Pharmaceutical
  158. iBio
  159. i-DNA Biotechnology 
  160. IDP Pharma
  161. ILC Therapeutics
  162. ILS (A subsidiary of Otsuka Chemical) 
  163. Imcyse 
  164. ImmuPharma
  165. Innovagen
  166. Inotrem
  167. Intavis Peptide Services
  168. Integrity Bio
  169. InterK Peptide Therapeutics
  170. Iris Biotech
  171. Issar Pharmaceuticals
  172. Jitsubo
  173. JPT Peptide Technologies
  174. Kaijie Peptide
  175. Kalos Therapeutics
  176. KareBayTM Biochem
  177. KeyBioscience
  178. Kinexus
  179. KriSan Biotech
  180. KYTHERA Biopharmaceuticals
  181. La Jolla Pharmaceutical 
  182. Lassogen
  183. LifeTein
  184. Longevity Biotech
  185. Lonza
  186. Lyotex
  187. MedImmune
  188. MElkin Pharmaceuticals
  189. MeSCue-Janusys
  190. Mimotopes
  191. MuseChem 
  192. Nanomerics
  193. Nanos
  194. Natco Pharma
  195. National Cancer Institute
  196. NervGen
  197. Neuland Laboratories
  198. Neuro-Bio
  199. New England Peptide
  200. NextPharma
  201. NoNO
  202. NovaCell Technology
  203. Novavax
  204. Novetide
  205. Novo Nordisk
  206. NSJ Prayog Life Sciences
  207. NUMAFERM
  208. ONL Therapeutics
  209. OPKO Health
  210. Oramed Pharmaceuticals
  211. ORPEGEN Peptide Chemicals
  212. Oryn Therapeutics
  213. Ovoca Bio
  214. Oxalo Therapeutics
  215. Oxurion
  216. Palatin Technologies
  217. Pepceuticals
  218. PEPDesign 
  219. Pepscan
  220. PEP-Therapy
  221. Peptide 2.0
  222. Peptide Institute
  223. Peptide Sciences
  224. Peptide Synthetics
  225. peptides&elephants
  226. Peptilogics
  227. PeptiStar
  228. Peptron
  229. Pfanstiehl
  230. PharmaMar
  231. Phoenix Pharmaceuticals
  232. piCHEM
  233. PIN Pharma
  234. Piramal Pharma Solutions
  235. PolyPeptide
  236. Polyphor
  237. PREVITALICA
  238. Priavoid
  239. PrimaPharma
  240. Primm Biotech
  241. Priveel peptides
  242. ProImmune
  243. ProLynx
  244. Promore Pharma
  245. ProNeurogen 
  246. Protagenic Therapeutics
  247. Protagonist Therapeutics
  248. Proteimax 
  249. Proteogenix
  250. ProvePharm
  251. Pulmotect
  252. Quantum Hi-Tech (China) Biological
  253. Radius Health
  254. Rani Therapeutics
  255. RegeneRx Biopharmaceuticals
  256. Revolo Biotherapeutics
  257. Rhythm Pharmaceuticals
  258. rPeptide
  259. RS Synthesis
  260. Salix Pharmaceuticals
  261. Sanofi
  262. Santhera Pharmaceuticals
  263. Sapience Therapeutics
  264. SBS Genetech
  265. Scancell 
  266. Schafer-N
  267. Scilight-Peptide
  268. ScinoPharm 
  269. Seachaid Pharmaceuticals
  270. Sekisui Medical
  271. Senn Chemicals
  272. Serpin Pharma
  273. Severn Biotech
  274. Shengnuo Peptide
  275. Shenzhen JYMed Technology
  276. Sinopep
  277. Soligenix
  278. Soricimed Biopharma
  279. Space Peptides
  280. STA Pharmaceutical (A subsidiary of WuXi AppTec)
  281. Stealth BioTherapeutics
  282. Sussex Research
  283. Symbiosis Pharmaceutical
  284. Synex
  285. SYNG Pharmaceuticals
  286. EOC Pharma 
  287. Takeda
  288. TCG
  289. TearSolutions
  290. TheraSource
  291. Theratechnologies
  292. Topas Therapeutics
  293. Tufts University Core Facility
  294. TwoToBiotech
  295. UCB Pharma
  296. Ulster University
  297. UNC Lineberger Comprehensive Cancer Center
  298. United Biosystems
  299. US Biological
  300. USV
  301. Valliscor
  302. Vault Pharma
  303. Vaxeal
  304. Viatem
  305. Vivtide
  306. Wilshire Technologies
  307. Wuhan Jetide Biotech
  308. Xaia Custom Peptides
  309. Xigen
  310. Zealand Pharma
  311. Zhangzhou Sinobioway Peptide
  312. Zhejiang Peptides Biotech
  313. Zucara Therapeutics

Source: www.nature.com/articles/s41586-021-04232-5

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.